Theve N O, Pousette A, Carlström K
Clin Oncol. 1983 Sep;9(3):193-7.
There are indications of possible effects of sex hormones on the pancreas. These include reports on steroid receptor proteins in pancreatic tissue, the purification and characterization of a highly specific, high capacity oestrogen binding protein in the human pancreas and capacity of human pancreatic tissue to convert the main peripheral oestrogen, oestrone sulphate, into the terminal biologically active oestradiol-17 beta. Furthermore, experiments in mice have shown accumulation of an anti-oestrogen, tamoxifen, in the pancreas. With this background, we have tried tamoxifen in 14 patients with unresectable adenocarcinoma of the pancreas. The median survival time was 8.5 months and three patients had a remarkably long survival time of 22 months. In a historical control group the median survival time was 2.5 months and no patients survived for more than 21 months. We have therefore started a randomized trial with tamoxifen in patients with unresectable pancreatic cancer. Even if anti-oestrogens are not the optimal form of therapy, other sorts of hormonal manipulation ought to be tried in pancreatic cancer.
有迹象表明性激素可能对胰腺产生影响。这些迹象包括关于胰腺组织中类固醇受体蛋白的报告、人胰腺中一种高度特异性、高容量雌激素结合蛋白的纯化和特性描述，以及人胰腺组织将主要外周雌激素硫酸雌酮转化为终末生物活性雌二醇-17β的能力。此外，在小鼠身上进行的实验表明抗雌激素他莫昔芬在胰腺中蓄积。基于此背景，我们对14例无法切除的胰腺腺癌患者试用了他莫昔芬。中位生存时间为8.5个月，3例患者生存时间长达22个月。在一个历史对照组中，中位生存时间为2.5个月，没有患者存活超过21个月。因此，我们启动了一项针对无法切除胰腺癌患者使用他莫昔芬的随机试验。即使抗雌激素并非最佳治疗方式，在胰腺癌中也应该尝试其他类型的激素治疗手段。
